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The return of the coronary stapler:
Will a new technique overcome an
old obstacle?
To the Editor:
I read with greatest interest the recent arti-
cle by Dr Suyker and colleagues.1 The au-
thors used a circular coronary stapler to
perform an end-to-side left internal tho-
racic artery (LITA)–to–left anterior de-
scending artery (LAD) anastomosis in 10
pigs. The procedure was performed on the
beating heart through a partial median ster-
notomy. Patency of the anastomoses was
confirmed by means of postmortem an-
giography, and histomorphologic evalua-
tion performed at 5 weeks after the opera-
tion showed a normal healing response.
A few comments seem to be appropriate
and of interest to the readership of the
Journal. The clinical use of circular coro-
nary stapling has a short yet fascinating
history.2 Vladimir P. Demikhov (1916-
1998) used the coronary stapling device in
the early 1950s to make LITA-to-LAD
end-to-end anastomoses in dogs and cadav-
ers.3 On the basis of Demikhov’s experi-
ments, Vasilii I. Kolesov (1904-1992) first
clinically applied the coronary vascular sta-
pler (VCA-4) on March 22, 1967, when he
constructed an end-to-end anastomosis be-
tween the LITA and LAD in a 52-year-old
man with class IV angina.4 Three years
later, the patient remained free of angina.
Kolesov subsequently used modified sta-
plers with prolonged bushing (Figure 1, A)
and vacuum suction to hold the LITA wall
while the stapling was performed (US
patent 4,350,160 of September 21, 1982).2
The coronary angiography performed al-
most 4 years after the operation with this
vacuum-facilitated stapler demonstrated
patent end-to-end anastomosis (Figure 1,
B). Thus it has already been demonstrated
that coronary stapling can be successfully
applied clinically. There were 3 main ob-
stacles that precluded the use of coronary
staplers in the early era of coronary sur-
gery.
First, it was easier and faster to perform
the anastomosis by hand either with or
without cardiopulmonary bypass. The
modern demands of achieving minimally
invasive coronary surgery through ever-
shrinking incisions reversed this. Both
Kolesov’s and Suyker’s staplers could be
adjusted to video-assisted robotic coronary
surgery.
Second, it was not possible to make an
end-to-side anastomosis with those early
staplers. The ingenious stapler described
by Dr Suyker and colleagues resolved this
problem.
The third and most significant obstacle
was the inability of the early staplers to bite
through the heavily atherosclerotic vascu-
lar wall. They chewed on it. The Kolesov
stapler overcame this obstacle in the late
1960s. It produced a perfect anastomosis in
heavily atherosclerotic coronary arteries.
Will the new stapler described by Dr
Suyker and colleagues overcome this ob-
stacle too?
It never ceases to amaze me how often
old ideas, which seemed utterly impractical
for many years, return to life. It seems that
what has been accomplished in surgery
never dies but rather remains dormant for a
number of years, waiting to be rediscov-
ered. The time of robotic and minimally
invasive coronary surgery has come, and
the coronary staplers are evolving under
the pressure of modern technology to find
their new applications. Are these stapling
devices here to stay this time?
Last but not least, I would like to con-
gratulate Dr Suyker and colleagues on their
fine experimental study. I am anxiously
awaiting the results of their clinical expe-
rience and hope that their stapler will be
more successful than its predecessors. If it
can successfully bite through the athero-
sclerotic vascular wall, it will have an enor-
mous effect on minimally invasive coro-
nary surgery.
Igor E. Konstantinov, MD
Division of Cardiovascular Surgery
Hospital for Sick Children
Toronto, Ontario, Canada
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Figure 1. A, Vascular circular stapler with prolonged bushing (VCA-PB) applied by V. I.
Kolesov and E. V. Kolesov in coronary surgery: 1, coronary artery; 2, internal thoracic
artery; 3, incision in the coronary artery; 4, bushing; and 5, prolonged bushing. From
Kolesov VI. The Surgery of Coronary Arteries of the Heart. Leningrad: Meditsina Publish-
ing; 1977. p. 163. B, Angiogram done in the late 1960s demonstrating patent end-to-end
anastomosis (arrow) applied by vacuum-facilitated stapler 3 years and 7 months after the
operation. Courtesy of Dr Evgenii V. Kolesov.
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Reply to the Editor:
We appreciate Dr Konstantinov’s encour-
aging words and fascinating account of the
early pioneering work on coronary staplers
by Drs Demikhov and Kolesov. We believe
that the S2 connector design is about to
overcome the 3 main obstacles that, ac-
cording to Dr Konstantinov, to date have
precluded the use of coronary staplers as
invented in the 1950s and 1960s.
First, S2 coronary stapling is an easier
and faster bypass grafting method than su-
turing manually. In subsequent open-chest,
beating-heart porcine studies the stapled
anastomosis was constructed in 1.8  0.6
(SD) minutes of coronary ischemia time
after preloading the graft (1.9  0.5 min-
utes) versus 11.8  2.7 minutes of isch-
emia time for the sutured anastomosis (P
.001, unpublished observation). Experi-
ments with the device endoscopically on
the beating heart look promising for both
anterior and posterior coronary arteries
(unpublished observation, Paul Gru¨nde-
man, MD).
Second, the S2 stapler can deal with
both side-to-side and end-to-side anasto-
moses because the latter is converted from
an initially side-to-side configuration by
clipping the very end of the graft. The
device uses the latest micromanufacturing
technology. As a result, it combines effec-
tive stapling and ease of use with minimal
connector mass and minimal exposure of
foreign body material to blood.
Third, the S2 device is designed to stay
close to basic surgical principles, which is
especially important when handling athero-
sclerotic vessels. The staples meet the ves-
sel walls in a standardized way, similar to
how a surgeon would position his needle,
and the applicator allows exerting a precise
and direct force on the staples to effect
penetration. Transmitting any undue forces
to the tissue is minimized to avoid trauma.
Tests with human explanted hearts have
shown that the system is capable of effec-
tively dealing with severely atherosclerotic
coronary arteries (unpublished observa-
tion). Clinical evaluation, however, is
needed to substantiate these results and de-
termine patency rates in human subjects.
The coronary stapler is indeed a concept
that has remained dormant for almost half a
century, waiting for both the proper tech-
nology and design to enable its effective
implementation. Without modern manufac-
turing technology, the present development
would have been prohibitively difficult.
Whether this time coronary stapling de-
vices are here to stay remains to be deter-
mined. Our current additional porcine data
at 3 months in 20 animals (unpublished)
warrant initiation of clinical evaluation.
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Value of intraoperative pleural
lavage in staging non–small cell
lung cancer
To the Editor:
We are pleased that our article1 warranted
an editorial and grateful to Dr D’Amico for
his thoughtful comments. Unfortunately,
there is a typographic error in the second
paragraph stating that “only 5 of the 292
patients had pathologic stage I or II dis-
ease.” Of course the denominator should be
13. Dr D’Amico mentions that our fol-
low-up was incomplete, but in fact we ac-
counted for all the patients in our study.
We accept the fact that the pleural la-
vage cytology results were positive in only
4.5% of our cases. However, this does not
render the technique of no value. Other
investigators have found a higher incidence
of positive pleural lavage (up to 38% in one
study).2 We believe that the value of a
prognostic indicator should be based more
on the discriminating ability of survival
than on the frequency alone. In our study,
positive lavage status was a more powerful
predictor than TNM stage.
Central to our study was a desire to
contribute to the discussion on the prognos-
tic impact of positive pleural lavage cytol-
ogy in patients who did not have a malig-
nant pleural effusion. All patients with any
macroscopic effusion were excluded from
the study. The Japan Lung Cancer Society
in its first English version3 states that “a
positive cytologic examination of intratho-
racic washings cannot be classified as T4”
without further comment on the appropri-
ate classification for this finding. The Inter-
national Union Against Cancer in its TNM
Supplement (a commentary on uniform
use)4 states, when considering peritoneal
lavage cytology, that “newer data suggest
that the worsening of prognosis as indi-
cated by positive lavage cytology may have
been overestimated” and recommends that
the addition of “cyve” to the T4 category
and R1 classification be applied in these
circumstances.
We hope that our data will inform the
debate for future revisions of the TNM
staging system.
Peter Goldstraw, FRCS
Eric Lim, MRCS
Department of Thoracic Surgery
Royal Brompton Hospital
London, United Kingdom
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